Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
CA 2355300 A1 · Owner: Gerlach, Uwe · Inventors: Gerlach, Uwe; Wei, Aguan; Lang, Hans, Jochen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the utilization of inhibitors of the KQT1 channel in order produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites. According to the invention inhibitors of the , KQT1 channel depict a novel lethal fundamental constituent for parasitic helminths and ectoparasites. Blockers of the cellular KQT1 channel said , channel occurring in the parasitic helminths and ectoparasites are therefore , used to produce a medicament for treating vertebrates and humans which are afflicted with the parasitic helminths or ectoparasites. These KQT1 blockers are used alone as medicaments or in combination with other medicaments and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 7, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 7, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 7, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.